Cyclopharma: Saint-Beauzire’s cyclotron is back in service
The cyclotron of Clermont-Ferrand, that has been dormant since two years, is back to service today. In 2015, the DENOS group acquired the Cyclopharma company and then decided that the Saint-Beauzire site was too old to be kept in operation. However, the head office of the group was maintained on the Biopôle Clermont-Limagne.
Thanks to a 500.000-€ investment, Cyclopharma relaunches now its cyclotron that will alleviate the 6 other production sites of the group. It will produce the FDG molecule (fluorodesoxyglucose), a radio tracer used with a PET Scan for the visualization of tumors.
The site of Saint-Beauzire ideally located in the center of France, allows a fast delivery of the customers, a main advantage for products with a life span of no more than 10 hours.
The return to service of the Cyclotron will also allow the 6 other sites to concentrate on the production of two new molecules, intended for the diagnosis of prostate cancers and breast.
Thanks to the last one, dedicated to the breast cancer, Cyclopharma is developing in the United States. The company intends moreover to invest a million euros in the American soil with as a bonus the installation of one to three sites before five years.